By InvitationNot Applicable

Laparoscopic Staging for Stage III Gastric Cancer

China968 participantsStarted 2025-02-01

Plain-language summary

This study aims to determine, through a multicenter randomized controlled design, the impact of precision treatment guided by laparoscopic staging on overall survival (OS), surgical conversion rate, and peritoneal metastasis rate in patients with clinical stage III gastric cancer, thereby providing evidence for precision staging and treatment decision-making.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pathologically confirmed: Histologically proven adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II/III).
✓. Definitive pathological markers: Documented status of HER2, MMR, CPS (PD-L1) score, and Claudin 18.2.
✓. Clinical stage: cT3/T4a N+ M0 based on contrast-enhanced CT, endoscopic ultrasound, or MRI (AJCC 8th edition):
✓. Age: 18 to 75 years, regardless of sex.
✓. Performance status: ECOG score 0-2 (fully active to ambulatory and capable of self-care but unable to work).
✓. Life expectancy: Estimated survival ≥ 6 months.
✓. Surgical fitness: Adequate cardiopulmonary functional reserve and no contraindications to anesthesia.
✓. Informed consent: Voluntary participation with written informed consent obtained.

What they're measuring

3-year Overall Survival (OS)

Timeframe: about 3 years

Trial details

NCT IDNCT07533825

SponsorTianjin Medical University Cancer Institute and Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Gastric Cancer (GC) trials